Julie Grant

Julie Grant is a Canaan General Partner focused on biopharma and company creation. Canaan’s official profile says she joined in 2013 and leads investments and formation efforts in companies that improve patient care. Her listed company work includes Day One Biopharmaceuticals, Reactive Biosciences, Nocion, Synthekine, Protagonist, Cellular Research, Dermira, Labrys Biologics, CytomX, and Unchained Labs. Before joining Canaan, she worked at Genentech on new oncology products across business development, commercial, and cross-functional management roles. Her official profile also states that she serves on the National Cancer Advisory Board, appointed by President Biden in 2023. She holds an MBA from Stanford GSB, an MPhil in BioScience Enterprise from Cambridge, and a BS in Molecular Biophysics and Biochemistry from Yale.